Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy
NCT06903923 on ClinicalTrials.gov · last registry update 2026-04-17
Recruiting now, toward 120 participants. Due to report 28 February 2030, alongside 7 other tracked readouts that quarter. Primary outcome, as filed: 24-month change in total vBMD at the distal radius. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P2
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- University of Virginia
- Sponsor type
- Other
- Enrollment
- 120
- Started
- 2025-07-31
- Primary completion
- 2030-02-28 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
24-month change in total vBMD at the distal radius
Conditions studied
Obesity in Children · Bone Strength · GLP - 1 · Lifestyle Modification · Bone Density · Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.